Literature DB >> 508550

The kinetics of salivary elimination of cyclophosphamide in man.

F D Juma, H J Rogers, J R Trounce.   

Abstract

1 The concentrations of cyclophosphamide in plasma and saliva were determined in seven patients following administration of single doses of cyclophosphamide during chemotherapy for lymphoma. 2 The saliva/plasma ratio was 0.77 +/- 0.24 (s.d.) and showed no time-dependence being rapidly established following intravenous and oral administration. 3 The T 1/2 of cyclophosphamide (8.38 +/- 2.25 h) determined from salivary measurements was not significantly different from that in plasma (8.24 +/- 2.60 h). It was not possible to estimate the apparent volume of distribution or total body clearance utilizing the salivary cyclophosphamide concentration without appropriate correction for the saliva/plasma concentration ratio. 4 The binding to the plasma protein of normal plasma of cyclophosphamide was 13.4 +/- 5.3%. The Scatchard plot for binding to bovine serum albumin indicates only weak binding to non-specific sites. 5 Salivary cyclophosphamide therefore indicates the concentration of the unbound fraction of plasma cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508550      PMCID: PMC1429824          DOI: 10.1111/j.1365-2125.1979.tb01025.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

Review 1.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Relationship between the pharmacokinetics and pharmacodynamics of procainamide.

Authors:  R L Galeazzi; L Z Benet; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

3.  Use of saliva in therapeutic drug monitoring.

Authors:  M G Horning; L Brown; J Nowlin; K Lertratanangkoon; P Kellaway; T E Zion
Journal:  Clin Chem       Date:  1977-02       Impact factor: 8.327

4.  Relationship between theophylline concentration in plasma and saliva of man.

Authors:  R Koysooko; E F Ellis; G Levy
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

5.  Mass spectrometric study of the distribution of cyclophosphamide in humans.

Authors:  J H Duncan; O M Colvin; C Fenselau
Journal:  Toxicol Appl Pharmacol       Date:  1973-02       Impact factor: 4.219

6.  Clinical pharmacology of cyclophosphamide.

Authors:  C M Bagley; F W Bostick; V T DeVita
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

7.  Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.

Authors:  I Jardine; C Fenselau; M Appler; M N Kan; R B Brundrett; M Colvin
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

8.  Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography.

Authors:  F D Juma; H J Rogers; J R Trounce; I D Bradbrook
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

  8 in total
  4 in total

Review 1.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  M J Moore
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

2.  Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions.

Authors:  H Schrøder; K B Jensen; M Brandsborg
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

3.  Biliary elimination of cyclophosphamide in man.

Authors:  J S Dooley; C A James; H J Rogers; R Stuart-Harris
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.